LUKE CHIOU: Open Payments
NPI 1063863546 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,682 in 93 payments from 14 companies in 2025. Trend: 2023 $1,396 · 2024 $979 · 2025 $1,682
Food & beverage: $1,682
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $285 |
| Otsuka America Pharmaceutical, Inc. | 12 | $261 |
| Neurocrine BioSciences, Inc. | 7 | $185 |
| ABBVIE INC. | 17 | $174 |
| Corium, LLC | 8 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $155 |
| Teva Pharmaceuticals USA, Inc. | 6 | $124 |
| Axsome Therapeutics, Inc. | 5 | $96 |
| Vanda Pharmaceuticals Inc. | 4 | $85 |
| Almatica Pharma LLC | 3 | $65 |
Products named: CAPLYTA, REXULTI, INGREZZA, VRAYLAR, Azstarys, TRINTELLIX, AUSTEDO XR, Auvelity.
Industry payments across AL — which companies pay providers there.
